Mechanistic insights into the peroxisome proliferator-activated receptor alpha as a transcriptional suppressor

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent hepatic disorders that 20-30% of the world population suffers from. The feature of NAFLD is excess lipid accumulation in the liver, exacerbating multiple metabolic syndromes such as hyperlipidemia, hypercholesterolemia, hypertension, and type 2 diabetes. Approximately 20-30% of NAFLD cases progress to more severe chronic hepatitis, known as non-alcoholic steatohepatitis (NASH), showing deterioration of hepatic functions and liver fibrosis followed by cirrhosis and cancer. Previous studies uncovered that several metabolic regulators had roles in disease progression as key factors. Peroxisome proliferator-activated receptor alpha (PPAR alpha) has been identified as one of the main players in hepatic lipid homeostasis. PPAR alpha is abundantly expressed in hepatocytes, and is a ligand-dependent nuclear receptor belonging to the NR1C nuclear receptor subfamily, orchestrating lipid/glucose metabolism, inflammation, cell proliferation, and carcinogenesis. PPAR alpha agonists are expected to be novel prescription drugs for NASH treatment, and some of them (e.g., Lanifibranor) are currently under clinical trials. These potential novel drugs are developed based on the knowledge of PPAR alpha-activating target genes related to NAFLD and NASH. Intriguingly, PPAR alpha is known to suppress the expression of subsets of target genes under agonist treatment; however, the mechanisms of PPAR alpha-mediated gene suppression and functions of these genes are not well understood. In this review, we summarize and discuss the mechanisms of target gene repression by PPAR alpha and the roles of repressed target genes on hepatic lipid metabolism, fibrosis and carcinogenesis related to NALFD and NASH, and provide future perspectives for PPAR alpha pharmaceutical potentials.

Automated summary

NAFLD is a common liver disease characterized by excessive lipid accumulation in the liver, which can progress to NASH, leading to liver dysfunction and fibrosis. Studies have shown that PPAR alpha plays a key role in hepatic lipid metabolism and its agonists may be novel drugs for treating NASH.